Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/02/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 05/19/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/19/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/18/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
